Table 2. Study population characteristics.

		CFH Y402H		ARMS2 A69S
Genotype	All	CC	CT	TT	TT	GT	GG
Genotype frequency	-	28 (31.1%)	47 (52.2%)	15 (16.7%)	26 (28.9%)	33 (36.7%)	31 (34.4%)
Lesion area	15.64	17.82	14.75	14.38	15.31	16.81	14.68
[mm2]	±10.63	±13.22	±10.26	±7.16	±11.88	±10.0	±10.4
Kruskal–Wallis test H (2, n=90)=0.6011253 p=0.74 H (2, n=90)=1.366674 p=0.505
Type of CNV	31:30	11:10:7	14:16:17	6:4:5	12:9:13	12:10:11	7:11:5
pdc:mc:oc	29
Kruskal–Wallis test H (2, n=90)=0.6248223 p=0.732 H (2, n=90)=4.495667 p=0.106
BCVA	41.79	40.28	43.51	39.2	41.31	38.79	45.39
[letters]	±14.52	±15.62	±14.19	±13.66	±16.47	±13.7	±13.26
Kruskal–Wallis test H (2, n=90)=1.164551 p=0.559 H (2, n=90)=3.937457 p=0.14
BCVA after 12 months	46.23	42.32	49.06	44.67	42.65	43.12	52.55
[letters]	±16.54	±16.77	±15.78	±17.82	±17.09	±16.93	±14.13
	(4.44±8.12)	(2.04±6.01)	(5.55	(5.47	(1.35	(4.33	(7.16
			±9.53)	±5.85)	±8.87)	±8.92)	±5.39)
	p<0.01	p=0.04	p<0.01	p<0.01	p=0.5	p<0.01	p<0.01
CSRT [µm]	331.95±99.05	333.71±85.53	332.85	325.87	312.85	338.18	341.35
			±100.22	±123.31	±103.54	±89.69	±105.55
Kruskal–Wallis test H (2, n=90)=1.164551 p=0.559 H (2, n=90)=3.937457 p=0.14
CSRT after 12 months [µm]	228.32	234.61	231.36	207.07	223.58	206.09	255.97
	±72.27	±80.08	±71.59	±58.35	±82.03	±46.69	±78.80
	(103.63±94.7)	(99.11	(101.49	(118.8	(89.27	(132.09	(85.39 ±91.98)
	p<0.01	±83.49)	±92.87)	±122.19)	±100.66)	±88.16)	p<0.01
		p<0.01	p<0.01	p<0.01	p<0.01	p<0.01
Injections	5.77±1.51	5.96±1.64	5.83±1.34	5.2±1.74	5.85±1.51	5.79±1.56	5.68±1.51

BCVA – best-corrected visual acuity, CNV – choroidal neovascularization (pdc-predominantly classic, mc-minimally classic, oc-occult), CSRT – central subfield retinal thickness